BrainsWay

BrainsWay is a global leader in noninvasive neurostimulation treatments for mental health disorders, founded in 2003 and dual-listed on NASDAQ and the Tel Aviv Stock Exchange. Headquartered in Burlington, MA, and Jerusalem, the company develops and commercializes its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology, utilizing patented H-Coil helmets for targeted brain stimulation. The Deep TMS™ system is the flagship offering, providing noninvasive treatment through electromagnetic pulses to stimulate deeper brain regions. It is FDA-cleared for major depressive disorder, obsessive-compulsive disorder, and smoking addiction. BrainsWay is committed to advancing neuroscience to improve mental health, emphasizing awareness and access to treatment options, particularly for those who do not respond to traditional therapies. The company also supports healthcare providers with education on the efficacy of its devices and protocols.